Skip to content

UroGen Pharma URGN Total Cost of Revenue

Discontinued — last reported Q2 '21

Total Cost of Revenue at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$3.42B+12.8%
Pfizer logo
PfizerPFE
$3.55B+24.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$8.11B+10.2%
Merck & Co. logo
Merck & Co.MRK
$4.2B+22.7%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$238K+310%
LQD
Liquidia CorporationLQDA
$1.52M+3.4%

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M
Operating income-$22.8M
Net income-$23.6M+46.2%
EPS (diluted)-$1.17

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.73B+71.7%

Profitability

See full
Gross margin89.7%
Operating margin-329.7%
Net margin-94.8%-25.6pp
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:CostOfRevenue.

The official record: UroGen Pharma’s 10-Q, filed August 4, 2021, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's total cost of revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's total cost of revenue?
UroGen Pharma (URGN) reported total cost of revenue of $1.43M in Q2 2021.
What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.